AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced a significant milestone in its fight against late-stage pancreatic cancer, as the first participant has been dosed in Phase 2 of its ongoing Phase 1b/2 clinical trial. The study, known as DURIPANC, investigates the potential of combining AIM's investigational drug, Ampligen (rintatolimod), with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab). This trial, taking place at the Erasmus Medical Center in the Netherlands, aims to enroll up to 25 patients who have metastatic pancreatic ductal adenocarcinoma.
CEO Thomas K. Equels expressed optimism regarding patient enrollment, noting that challenges related to subject accrual often encountered in pancreatic cancer research are not expected to hinder progress in this particular study. The trial’s design allows for several participants from the successful Phase 1 segment, particularly those who received the highest dose, to continue into Phase 2.
Ampligen, a first-in-class candidate and TLR-3 agonist, aims to boost the immune response against cancer cells, showing promise across various cancers and viral diseases. The trial's exploration of combining Ampligen and durvalumab could provide new therapeutic avenues for patients facing a disease characterized by limited treatment options and poor prognosis.
As AIM progresses in its clinical studies, the company emphasizes its commitment to transparency regarding forward-looking statements, cautioning investors of the inherent risks and uncertainties associated with clinical research and drug approval processes. For updates and additional information about DURIPANC and AIM's research endeavors, interested parties can visit ClinicalTrials.gov or the company's official website.
MWN-AI** Analysis
AIM ImmunoTech Inc.’s recent announcement regarding the initiation of the Phase 2 study of Ampligen combined with AstraZeneca’s Imfinzi as a potential treatment for late-stage pancreatic cancer has significant implications for investors. This could position AIM at the forefront of a highly competitive oncology market, particularly given the low survival rates associated with pancreatic cancer.
One notable aspect of the DURIPANC trial is AIM's commentary on their expectations regarding patient enrollment, which could mitigate a common hurdle in clinical trials. A steady pace of recruitment may not only indicate well-managed clinical operations but also bolster investor confidence in the trial's success.
That said, potential investors should remain cautious. Clinical trials, particularly in oncology, are fraught with uncertainty, and the leap from early-stage trials to market approval is significant. AIM's risks, as highlighted in their cautionary statements, are valid considerations. The company has yet to establish a clear pathway to commercialization, and Ampligen's efficacy for pancreatic cancer remains unproven.
Investors should keep an eye on upcoming clinical data releases and any strategic partnerships that AIM may pursue, which could enhance its market position and credibility. Furthermore, tracking the performance of Imfinzi in other oncology contexts may provide insights into the combined therapy's potential and broader market reception.
From a valuation perspective, AIM shares may experience volatility. Speculative trading could be expected around trial milestones, making it a potentially high-reward investment for those who can tolerate accompanying risks. Considerations around risk exposure, portfolio diversification, and investment horizon will be key factors in determining appropriate positioning in AIM's stock. As developments unfold, near-term technical analysis alongside fundamental evaluation will aid investors in navigating this pharmaceutical landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 clinical trial involving AIM’s Ampligen (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi ® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”). Several subjects from Phase 1 who received the highest dose will also be included in Phase 2.
DURIPANC is an investigator-initiated, exploratory, open-label, single-center study in the Netherlands at the Erasmus Medical Center. Up to 25 patients are expected to be enrolled in the Phase 2 portion of DURIPANC.
AIM CEO Thomas K. Equels stated: “Unlike with many pancreatic cancer studies where accrual can be a major obstacle, we expect to continue to enroll subjects in Phase 2 of DURIPANC at a steady pace.”
Read more at about DURIPANC at ClinicalTrials.gov NCT05927142 – “ Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy (DURIPANC) “
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
How does AIM ImmunoTech Inc.'s collaboration with AstraZeneca on the DURIPANC study aim to improve treatment outcomes for late-stage pancreatic cancer patients?
What specific challenges does AIM ImmunoTech Inc. anticipate in enrolling subjects for the Phase 2 trial, and how does the company plan to address them?
Can AIM ImmunoTech Inc. provide more details on the preliminary results from Phase 1 that led to the dosing of the first subject in Phase 2 of the DURIPANC trial?
What are the potential implications for AIM ImmunoTech Inc. if Ampligen (rintatolimod) successfully demonstrates efficacy in treating pancreatic cancer during the ongoing clinical trials?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
